Diabetes Clinical Trials in Tennessee

Showing 421-440 of 611 trials

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

NCT01413542

The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.

HypertensionDiabetes Type 2

Vanderbilt University44 participantsStarted Nov 2011

Nashville, Tennessee, United States

COMPLETEDPhase 371 miles

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

NCT01131676

The aim of the present study is to investigate the safety of BI 10773 treatment in patients with Type 2 Diabetes Mellitus and high cardiovascular risk.

Diabetes Mellitus, Type 2

Boehringer Ingelheim7,064 participantsStarted Jul 2010

Birmingham, Alabama, United States • Birmingham, Alabama, United States • Huntsville, Alabama, United States +612 more locations

Pharmacogenetics of Ace Inhibitor-Associated Angioedema

BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).

Diabetes Trials in Other Cities

12 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Patients With Type 2 Diabetes Mellitus

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes

Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes

Comparison of TAK-875 (Fasiglifam) With Placebo in Participants With Type 2 Diabetes

Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults

Glucose Meter Study

Trial of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Multiple Ascending Dose Study in Subjects With Type 2 Diabetes

Immunosuppressive Medications for Participants in ITN005CT (NCT00014911)

Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

Strategies to Improve Islet Survival

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes

Study of an Investigational Glucose Meter System

G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator

Other Conditions in Tennessee